President Trump’s executive order directing DOJ to move cannabis to Schedule 3 would eliminate Section 280E of the Internal Revenue Code, removing the rule that has prevented Aurora Cannabis from deducting basic business expenses. Under current Schedule 1 status, Aurora and other U.S. operators are taxed as if they were “narcotics traffickers,” disallowing deductions for payroll, rent, marketing and other operating costs. Moving to Schedule 3—aligned with substances recognized for medical use—would immediately improve Aurora’s cash flow by restoring full deductibility of standard expenses, potentially boosting profitability and freeing up capital for expansion and product development.

Over the past six months, Aurora Cannabis shares have declined by approximately 10%, marking them as one of the weaker performers among U.S.-listed cannabis issuers. Year to date, the stock is down about 2.5%, though it has delivered a one-year gain of roughly 8.5%. This contrasted with an outperformance by certain cannabis ETFs in 2025, highlighting that Aurora’s recovery will depend on both federal policy progress and execution on cost reduction and revenue diversification initiatives.

In its most recent quarterly report, Aurora reported consolidated revenue of $246.7 million, up modestly from the prior year period. Net income was positive at $1.6 million, translating to an EPS loss of $0.69 after accounting for non-cash impairment charges and restructuring costs. The company’s price-to-sales ratio stands at 0.97, reflecting subdued market valuations, while the trailing price-earnings ratio is negative due to perennial non-cash adjustments. Investors will watch upcoming quarters for evidence that federal tax relief and operational streamlining translate into sustainable margin expansion.

Aurora benefits from strong institutional support, with 47.6% of outstanding shares held by large money managers and endowments. Insider ownership remains minimal at 0%, keeping decision-making squarely in the hands of the board and institutional stakeholders. Analyst coverage is mixed: of three active ratings, one recommends selling, one holding and one strong buy, resulting in an average score of 2.33 on a four-point scale. The divergent views underscore the sector’s volatility and hinge on timing of federal reform, U.S. exchange listing access, and banking safe-harbor provisions.